S
ick neonates are one of the most heavily transfused groups of patients in modern medicine. However, despite considerable research, most neonatal transfusion practice remains opinion based rather than truly evidence based. Most neonatologists would not prescribe drugs to their patients unless there was a reasonable expectation of benefit. Unfortunately, this rigour does not translate to the prescription of blood products, and as a result there exists a diversity of opinion and practice between different clinicians 1 and different institutions. [2] [3] [4] [5] [6] Clearly the administration of blood products conveys a finite risk of transmitting potentially serious infections [7] [8] [9] and is not without risk and cost. 7 8 It therefore remains a continuing task to define and refine the most clinically appropriate protocols for blood product use in neonates, within the constraints of the available evidence. With these goals in mind this paper reviews recent literature and research on neonatal transfusion practice and proposes practical transfusion guidelines and trigger thresholds for commonly used blood products in neonatal medicine.
RED BLOOD CELLS
Packed red blood cells (RBCs) are the most common blood product administered to sick neonates. Many previous studies (reviewed in refs 10 11 ) have attempted to define their optimal use in neonates. However, rapidly changing patient populations and characteristics over the last decade, coupled with the introduction of increasingly rigorous transfusion protocols, have reduced the relevance of much of this previous work to modern neonatal practice. Progress in RBC transfusion practice therefore requires a fundamental re-evaluation of its basic aims.
At the most basic level, RBC transfusions are required for two reasons:
N to ensure adequate tissue oxygenation during intensive care periods N after intensive care, to treat clinically significant symptomatic anaemia However, neither clinical situation is straightforward to define.
Tissue oxygenation

Ensuring adequate tissue oxygen delivery
Tissue oxygenation is influenced by the concentration and type of haemoglobin (Hb), the concentration of 2,3-diphosphoglycerate within RBCs (both factors affect the Hb-oxygen dissociation curve and thus the oxygen unloading capacity of the blood), and the cardiopulmonary function of the neonate. Apart from Hb concentration, none of these variables are easily measurable in everyday neonatal practice. In addition, assuming optimised cardiopulmonary function during intensive care, apart from altering Hb concentration by transfusion (and thereby Hb type and 2,3-diphosphoglycerate concentration by exchanging HbF for HbA RBCs), little can be done to influence these variables on an hour to hour or day to day basis. Thus RBC transfusion remains the only ''haematological'' treatment option available that has the potential to significantly influence tissue oxygen delivery. However, the question remains how to recognise when a neonate is developing Hb limited oxygen unloading capacity to the tissues and how to measure this accurately in everyday practice?
Methods of assessing tissue oxygenation
Peripheral fractional oxygen extraction (FOE)
Direct measurement of tissue oxygenation is not possible. However, surrogate measures have been attempted. Recently, Wardle et al 12 measured peripheral FOE by near infrared spectroscopy as a surrogate measure of the adequacy of tissue oxygen delivery in 74 neonates , 1500 g undergoing standard neonatal care. High peripheral FOE (. 0.47) was taken as a cut off point suggesting inadequate tissue oxygen delivery and thereby the potential for inadequate tissue oxygenation. This parameter was used as an RBC transfusion trigger in 37 neonates, with the remaining 37 neonates receiving RBC transfusion guided by a conventional Hb based protocol. Although there was a trend towards fewer RBC transfusions in the FOE group, this was not significant. However, neonates in the FOE group had lower median Hb during the study, and time to first transfusion from study entry was also longer. No difference in major neonatal complications was seen between the two groups, suggesting that no clinical compromise occurred in the neonates in the FOE group. Interestingly, two thirds of transfusions in the FOE group were given because of clinical concerns about low Hb or symptoms and not because of high FOE. Thus, this method of assessing trigger thresholds for RBC transfusion in preterm neonates deserves further assessment, as sticking closely to high FOE as a transfusion trigger may prove to be a practical method to further reduce RBC transfusions and donor exposure without adversely affecting outcome.
Capillary whole blood lactate
Lactate concentration has also been assessed as an indicator of tissue oxygenation and/or the need for RBC transfusion. [13] [14] [15] [16] In the intensive care period, lactate concentrations are highly variable, probably reflecting variations in tissue perfusion rather than Hb limited oxygen unloading capacity to the tissues. Therefore, during intensive care, lactate concentrations are not useful in deciding the need for RBC transfusion. In stable neonates, these concentrations have been shown to decrease after RBC transfusions given for ''symptomatic'' anaemia. 13 15 16 However, even in stable preterm neonates, lactate concentrations show considerable variation during a 24 hour period, 13 and before transfusion they do not correlate with Hb or packed cell volume. 13 Thus, peripheral blood lactate concentrations may be useful in the overall assessment of tissue perfusion/oxygenation, but on their own are not a reliable indicator of the need for RBC transfusion.
In summary, with currently available techniques, there is no practical method applicable to everyday neonatal practice that accurately and reproducibly assesses tissue oxygenation.
Trends in clinical practice
As high quality methods for assessing tissue oxygenation are not available, observational clinical studies of RBC transfusion practice represent the best available evidence to guide future developments. Over the past 15 years, a number of groups have reported on this subject in preterm neonates. Most of these reports show a definite trend towards decreased use of RBC transfusions, even in the most preterm neonates. [17] [18] [19] [20] Importantly, there is no suggestion that this results in an increased need for respiratory support or oxygen therapy or poorer weight gain or increased length of hospital stay. 3 12 In addition, there is not an increased incidence of important neonatal complications, such as intraventricular haemorrhage (IVH), necrotising enterocolitis (NEC), chronic lung disease of prematurity (CLD), or sepsis, in preterm neonates managed with a restrictive RBC transfusion policy. 3 There is less evidence from the converse situation-that is, does maintaining a high Hb improve outcome in preterm neonates? However, Brooks et al, 21 who looked at maintaining a packed cell volume . 40% in preterm neonates in an attempt to reduce retinopathy of prematurity, also reported no reduction in important neonatal complications (IVH, CLD, NEC) as secondary outcome measures. This study only assessed preterm neonates greater than 28 days of age-that is, outside the intensive care period. However, the fact that a low Hb or packed cell volume by itself (as opposed to clinical concern about the adequacy of tissue oxygenation) is the sole trigger factor for transfusion in many intensive care situations 12 22 suggests that Hb limited oxygen unloading capacity to the tissues is rare, even during intensive care. In modern neonatal care, this is increasingly the case in the era of antenatal steroids, surfactant, limited acute lung disease, nasal continuous positive airways pressure, and low oxygen requirement.
Guidelines for transfusion of RBCs
Taking into consideration the available evidence, we use the following RBC transfusion practice in neonates.
Packed RBC product
The British Committee for Standards in Haematology (BCSH) Transfusion Task Force 23 recommends the following.
N Components for transfusion in utero or to children under 1 year of age must be prepared from donors who have given at least one donation within the previous two years that was negative for all mandatory microbiological markers.
N Dedicating aliquots from a single donation to allow sequential transfusions from the same donor for neonates/small children who are likely to be repeatedly transfused is considered good practice.
N Components transfused in the first year of life should be cytomegalovirus seronegative (since November 2001 all cellular blood products in the United Kingdom have been leucocyte depleted before hospital issue and are widely regarded as cytomegalovirus safe; nevertheless, in the absence of controlled trials, the BCSH continues to recommend cytomegalovirus negative products for infants).
For a full discussion of recommendations for blood components for use in the newborn, the reader is referred to the BCSH guidelines web site. 23 
Dose (volume) of RBCs
In preterm neonates the small amount of research available suggests that large volume (20 ml/kg) RBC transfusions lead to larger rises in Hb and fewer overall transfusions than small volume transfusions (10 ml/kg). 24 This volume of packed RBCs is well tolerated in the vast majority of preterm neonates. 24 
Triggers for RBC transfusion
Adhering closely to strict transfusion guidelines reduces transfusion number and donor exposure. 18 25 This, together with the above data, strongly suggests that the most appropriate RBC transfusion strategy for sick neonates is a large volume restrictive approach directed by strict guidelines using dedicated blood products from a single donation. Table 1 presents suggested RBC transfusion triggers. However, it must be stressed that these trigger levels are only guidelines and some neonates will have no clinical compromise at these Hb concentrations/packed cell volumes and therefore will not automatically require RBC transfusion.
PLATELETS
Previous studies suggest that neonatal thrombocytopenia is a risk factor for haemorrhage (particularly IVH), [26] [27] [28] [29] [30] mortality, 26 27 31 32 and adverse neurodevelopmental outcome. 29 Therefore the sole reason for administering platelet transfusions must be to positively influence these outcomes. However, to date, there has been no neonatal trial that shows reduced haemorrhage or improved outcome in neonates with non-immune mediated thrombocytopenia treated with platelet transfusions. In the only randomised controlled trial addressing this, Andrew et al 33 found no benefit in terms of haemorrhage when maintaining a normal platelet count by platelet transfusion in a study of preterm neonates compared with controls with moderate thrombocytopenia (platelets (50-150) 6 10 9 /l).
Studies of contemporary platelet transfusion practice in neonates Despite the observations described above, sick neonates with thrombocytopenia are often given platelet transfusions. Three recent publications [34] [35] [36] retrospectively document platelet transfusion practice in three separate neonatal intensive care units in the United States, United Kingdom, and Mexico. Despite the geographical differences, several common themes are apparent in these reports. N More than half of neonates given platelet transfusions receive more than one transfusion, with a significant proportion receiving more than four transfusions.
N Thrombocytopenic neonates who receive platelets are up to 10 times more likely to die than neonates who do not receive platelet transfusion (however, the severity of the clinical conditions causing the thrombocytopenia is stressed in all three reports as the major factor leading to mortality, as is the relative rarity of uncontrolled haemorrhage as a direct cause of death in such neonates).
N The uncertainties surrounding platelet transfusions make the exploration of alternative treatments for thrombocytopenia, particularly haemopoietic growth factors (see below), a worthwhile aim.
Developing guidelines for platelet transfusion Many platelet transfusion guidelines for the newborn have been proposed. However, we have used these recent clinical reports [34] [35] [36] to develop more realistic guidelines for platelet transfusion in different groups of sick neonates (table 2) , by coupling modern practice with what is already known about the incidence and natural history of haemorrhage in sick neonates.
Haemorrhage in sick neonates
Most neonates who bleed (particularly those with IVH) do so in the first days of life. However, with the exception of perinatal asphyxia, the conditions precipitating most episodes of severe thrombocytopenia-for example, late onset sepsis and NEC-usually develop after the first few days of life. 34 As highlighted above, patients with these complications rarely have major haemorrhage, even when severely thrombocytopenic. Thus, we believe that prophylactic platelet transfusions are not required for such patients until the platelet count falls below 30 6 10 9 /l (table 2). Indeed many patients many not be at significant risk of haemorrhage until the platelet count falls much lower. We recommend a higher trigger level (, 50 6 10 9 /l) for patients with the greatest risk of haemorrhage, especially extremely low birth weight neonates (, 1000 g) in the first week of life and neonates with significant clinical instability-for example, fluctuating ventilation requirements or blood pressure (table 2) . Platelet transfusions in neonates with platelet counts . 50 6 10 9 /l should be reserved for patients with active major bleeding-that is, pulmonary, gastrointestinal, renal-as there is no evidence that higher platelet counts are of any benefit in non-bleeding neonates.
Dose and product
No trial evidence is currently available on the optimal volume (dose) of platelets to administer or when to administer further transfusions. As with RBCs, larger volumes (20 ml/ kg) appear to result in larger and more sustained rises in platelet count compared with smaller volumes (10 ml/kg) (personal observations). However, a small number of neonates whose thrombocytopenia is the result of severe platelet consumption-that is, in NEC-may not show any appreciable response to even repeated platelet transfusions, and the value of such treatment is questionable given the current paucity of trial evidence. For guidance on appropriate platelet products, the reader is referred to the BCSH web site. 23 
FRESH FROZEN PLASMA
Traditionally fresh frozen plasma (FFP) has been administered to neonates for a variety of reasons: Except for treatment of DIC (which may also require the administration of cryoprecipitate or specific clotting factors), there is no evidence to support the use of FFP in the other clinical situations listed above. 37 Prevention of IVH The large study conducted by the Northern Neonatal Network and reported in 1996 38 clearly shows that prophylactic FFP administered to preterm neonates at birth does not prevent IVH or improve outcome at 2 years of age. 
Sepsis
Although FFP is often used as an adjuvant therapy during neonatal sepsis, 5 there have been very few studies that have assessed its efficacy in this clinical situation. Krediet et al 41 looked at rises in immunoglobulin G levels and increases in opsonising activity against coagulase negative Staphylococcus in preterm neonates given FFP during clinical episodes of sepsis. They found variable changes in both variables and no influence on outcome.
During neonatal thrombocytopenia DIC is present during only 10% of episodes of neonatal thrombocytopenia. 26 34 Therefore the ''blind'' administration of FFP to thrombocytopenic neonates is not indicated unless there is good clinical or laboratory evidence of concurrent DIC.
Prolonged indices of coagulation
Normal values for indices of coagulation have now been established for both term 42 and preterm neonates. 43 However, many newborns transiently exhibit abnormal indices of coagulation which are not accompanied by clinical evidence of bleeding and which spontaneously improve over the first days of life. There is no evidence that ''correcting'' these indices reduces episodes of haemorrhage or improves outcome. 30 The decision to administer FFP in this situation must be guided by the overall clinical condition of the neonate and not simply by the desire to ''treat the numbers''. Dose, guidelines, and product When used as a source of clotting factors the largest volume appropriate to the cardiovascular status of the neonate should be administered. As above, the only indications for FFP in neonates recommended in the recent BCSH guidelines and supported by evidence are: 23 44 45 N DIC N vitamin K dependent bleeding N inherited deficiencies of coagulation factors.
For guidance on FFP products suitable for neonates, the reader is referred to the BCSH web site. 23 
HUMAN ALBUMIN SOLUTION
Human albumin solution (HAS) is used as a primary volume replacement solution for sick newborns. However, HAS is not superior to other colloid or crystalloid solutions as a volume replacement solution in standard neonatal practice. 46 Concentrated HAS solutions (20%) are sometimes administered to hypoalbuminaemic neonates with clinically significant peripheral oedema in an attempt to correct the hypoalbuminaemia, ameliorate the oedema, and hasten clinical improvement. However, there is no convincing evidence to support this practice, 47 and, as the underlying cause of the hypoalbuminaemia in this situation is almost always inadequate nutritional support, optimising nutrition is the preferred option. As the use of HAS in intensive care patients is associated with excess mortality, 48 together these data suggest that there is no valid indication for the use of HAS in standard neonatal practice.
NORMAL HUMAN IMMUNOGLOBULIN
Normal human immunoglobulin (NHI) is standard treatment for both alloimmune and autoimmune neonatal thrombocytopenia and is generally administered to neonates in both clinical situations at platelet counts below 30 6 10 9 /l. (Platelet transfusion may also be necessary depending on the clinical condition of the neonate; table 2.) Platelet counts will usually rise promptly after NHI at a dose of 1 g/kg on two consecutive days (in single or divided doses). Further courses may be required in refractory or relapsing cases.
There have now been a considerable number of trials assessing the value of NHI as both prophylaxis and adjuvant therapy for neonatal sepsis. A full review of these is beyond the scope of this article. However, Cochrane reviews of both situations suggest that prophylactic NHI is not protective against neonatal sepsis, 49 but it may be beneficial when given in conjunction with standard treatment for neonatal sepsis. 50 An international multicentre trial is underway to further address this question. When administered during sepsis the standard recommended dose is 500 mg/kg as a single dose.
Recent systematic reviews have found that treatment of neonates with alloimmune haemolysis with NHI does reduce the need for exchange transfusion. 51 52 However, the number of studies and infants included is small, and further well designed studies are needed before NHI can be fully recommended for the treatment of neonatal alloimmune haemolysis. 51 52 
EXCHANGE TRANSFUSION/DILUTIONAL EXCHANGE
As severe Rh haemolytic disease of the newborn becomes increasingly rare because of a combination of maternal anti-D therapy and intrauterine transfusion of affected fetuses, neonatal exchange transfusion is also becoming an increasingly rare procedure. 53 When severe haemolytic disease of the newborn is present, exchange transfusion may be used to manage:
N severe anaemia at birth complicated by heart failure (where top up transfusion may exacerbate both fluid overload and heart failure) N hyperbilirubinaemia Exchange transfusion is usually carried out by repeatedly exchanging small samples (5-10 ml/kg) of blood through an umbilical venous catheter situated in the inferior vena cava or inferior vena cava/right atrium junction. (The procedure can also be carried out by removing blood from an arterial catheter and replacing blood by continuous infusion into a peripheral or central vein. However, individual units should maintain a standard practice; see below.) When anaemia and heart failure are the most pressing clinical problems, then a single blood volume exchange transfusion (80-100 ml/kg) may be sufficient to ameliorate these problems. However, in the treatment of severe haemolytic disease of the newborn, the aim is to remove both the antibody coated red cells (to reduce further haemolysis and bilirubin production) and the bilirubin already in the circulation. In this situation, a double blood volume exchange transfusion (160-200 ml/kg) is recommended and is estimated to remove 90% of the initial RBCs and 50% of the available intravascular bilirubin. 23 In most cases in the United Kingdom, plasma reduced blood with a packed cell volume of 0.50-0.60 is used for exchange transfusion to manage both severe anaemia and hyperbilirubinaemia.
In view of the decreasing general experience of the practice of exchange transfusion, all neonatal units must adopt and maintain appropriate written practice guidelines for this procedure. For a fuller discussion of RBC products suitable for exchange transfusion, the reader is referred to the BCSH guidelines for this procedure. 23 Dilutional exchange transfusion is undertaken to reduce whole blood viscosity in neonates with polycythaemia. Whole blood viscosity rises exponentially when the packed cell volume exceeds 0.65-0.70. 54 However, even at packed cell volumes . 0.70, only a minority of neonates exhibit hyperviscosity, 55 56 and, in practice, different neonates appear able to ''cope'' with different packed cell volumes to a highly variable extent. Performing a dilutional exchange on all neonates with a free flowing venous packed cell volume of . 0.70 is one method of ensuring treatment for all neonates at risk of hyperviscosity. However, the few follow up studies of the outcome of neonates treated in this way do not show a definite benefit of this strategy. 55 57 Indeed it appears that only neonates with proven hyperviscosity are at risk of an adverse neurological outcome. 58 In practice, there would seem to be two ways to resolve this dilemma: measure whole blood viscosity in all neonates found to be polycythaemic and proceed accordingly, or only perform dilutional exchange transfusion in neonates with a packed cell volume . 0.65-0.70 who have symptoms that suggest a possible adverse outcome (principally neurological symptoms, such as fits, excessive jitteriness, neurological signs, refractory hypoglycaemia). Minor symptoms likely to resolve without risk of adverse outcome-for example, poor peripheral perfusion or borderline hypoglycaemia-can be treated by standard methods until polycythaemia/hyperviscosity resolves spontaneously. We recommend this approach as the most practical for busy maternity/neonatal units.
It should always be remembered in the assessment and treatment of such neonates that umbilical venous catheterisation and dilutional exchange are not without complications. 59 When considered clinically appropriate, a one third whole blood volume exchange (80 ml/kg) is usually performed. There is no justification for using other than normal saline as the exchange fluid. 60 
HAEMOPOIETIC GROWTH FACTORS
In the last decade there has been considerable interest in the potential for haemopoietic growth factors to ameliorate the major haematological problems seen in sick neonates. Again a full review of this subject is beyond the scope of this article. However, it is clear that despite a large amount of research effort, no haemopoietic growth factor has yet found a clear role in standard neonatal practice.
ERYTHROPOIETIN
There have now been numerous studies assessing the value of recombinant human erythropoietin (rhEPO) administered to preterm neonates to ameliorate anaemia (reviewed in refs [61] [62] [63] ). It is quite clear that rhEPO stimulates erythropoiesis, increases indices of RBC production, and reduces RBC transfusion requirement. Although there has been a report of aplastic anaemia developing in adults chronically treated with rhEPO, 64 this complication has not been seen in neonates. The greatest reduction in transfusion requirement is seen when rhEPO is begun as soon as possible after birth 65 and at high dose (750-1500 IU/kg/week). Inadequate iron and protein intake limit the effectiveness of rhEPO. [66] [67] [68] Despite these positive findings, the overall reduction in RBC transfusion requirement in preterm neonates treated with rhEPO is disappointingly small. [61] [62] [63] This is mainly due to the lag time of one to two weeks between beginning treatment and any rise in packed cell volume. As roughly two thirds of all RBC transfusions given to preterm neonates are administered in the first three weeks of life, [17] [18] [19] [20] it is easy to see why even optimally administered rhEPO treatment makes little overall impact on RBC transfusion requirement. rhEPO treatment does significantly increase the number of very low birth weight neonates who do not require any RBC transfusion before discharge, 65 and this may be seen as a worthwhile clinical outcome. However, treating all such neonates with an rhEPO dose regimen able to achieve this outcome is expensive and labour intensive. Such a strategy also entails giving ''unnecessary'' treatment to the one third of very low birth weight neonates who would receive no RBC transfusion even without rhEPO therapy. 69 70 In addition, as RBC transfusion strategies in preterm neonates become increasingly restrictive, it becomes more difficult for rhEPO treatment to achieve a clinically useful reduction in overall transfusion requirement. In conclusion, with the current level of safe RBC products available, rhEPO treatment cannot be recommended to ameliorate anaemia in standard neonatal practice. However, if the supply of safe RBC products declines in the future, rhEPO treatment for preterm neonates may require re-evaluation.
RECOMBINANT HUMAN GRANULOCYTE AND GRANULOCYTE/MONOCYTE STIMULATING FACTORS
Both these agents increase granulocyte counts in preterm neonates and appear to be free of major side effects. [71] [72] [73] [74] [75] However, the available evidence suggests that neither agent given as prophylaxis, or as adjuvant therapy during neonatal sepsis, significantly improves outcome. [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] Further trials are in progress, but again these agents cannot, as yet, be recommended in the treatment of sepsis in standard neonatal practice. [76] [77] [78] [79] [80] 
THROMBOPOIETIN AND INTERLEUKIN 11
Both these agents are currently being evaluated in adults and children for their ability to stimulate platelet production and ameliorate thrombocytopenia. 81 82 However, neither agent has been used in neonates, and it is likely that similar lag problems will be seen with these agents in the treatment of neonatal thrombocytopenia 83 as outlined above for rhEPO and anaemia.
CONCLUSION
Many previously widely accepted neonatal transfusion practices are changing as neonatologists become more aware of the risks to their patients of multiple blood product transfusions. Transfusion practices are generally becoming more restrictive, and inappropriate use of blood products is reducing. To continue this improvement neonatologists must:
N apply the same rigour to blood product use in neonates as is seen with drug therapy N design and conduct appropriate randomised controlled trials of blood product use in neonates to define the best evidence based practice N construct, adhere closely to, and regularly audit and review guidelines for the administration of all blood products to sick neonates.
